Clinical Trial Details
— Status: Not yet recruiting
Administrative data
NCT number |
NCT05227235 |
Other study ID # |
INGN22SG035 |
Secondary ID |
|
Status |
Not yet recruiting |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
August 1, 2022 |
Est. completion date |
March 31, 2023 |
Study information
Verified date |
February 2022 |
Source |
NHS Greater Glasgow and Clyde |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
This randomised controlled trial will provide definitive answers to whether a 3D telemedicine
system makes a remote consultation more similar to meeting a doctor face-to-face, than a 2D
Telemedicine consultation. This will be measured using a "Presence" scale - which is a
measure of the realism or immersion of the system - and is of key importance as preliminary
data from the research team's feedback studies found that realism of a clinical consultation
correlates strongly with patient satisfaction. Patient satisfaction is seen by many
healthcare systems as primary evidence of efficacy of treatment and as a strong determinant
of overall health outcomes. Further outcome measures in this trial will assess patient
satisfaction, usability, and mental effort.
Description:
1. Pre-study Protocol Optimisation Focus group research and co-design with patients from
2019 to 2021, has been used to allow protocol optimisation prior to the RCT. This part
of the research project has already been completed by the research team.
2. Pre-study Glasgow Telemedicine Scale Validation Prior to the RCT the research team will
validate the Glasgow Telemedicine Scale. This has been developed with experts in digital
health, clinicians and patients, and also from the feedback data from previous research.
This will involve a group of 20 patients who will attend the Telemedicine clinic and use
both the 3D and 2D telemedicine systems without randomisation. Patients who participate
in the validation study will complete the questionnaire on their first visit, and return
at 6 weeks to use the system again and complete the same questionnaire again.
3. Approach and Design This study will use a randomised crossover design for the primary
outcome measure (Single Item Presence Questionnaire). Patients will be randomised to
either the 3D or 2D Telemedicine consultation first, and then crossover to the other
Telemedicine system. A crossover design has been used in other digital research trials
by the research group, as a washout period is not mandatory for tests of perception
(such as Presence) as opposed to tests of knowledge. Additionally, plastic surgery
patients are known to have a very heterogenous mix of operations and anatomical areas,
and a crossover design will account for this heterogeneity better than a
between-subjects design. Patients will therefore act as their own controls. Carry-over
effects will be analysed in this study. However, to exclude carry-over effects, the
study will also analyse the outcome measures between-subjects for the first Telemedicine
system used. In these analyses, 2D Telemedicine will be the control group and 3D
Telemedicine will be the "intervention" group. The study will be adequately powered to
account for within and between subjects outcomes analyses in this trial.
Sample Size Sample sizes were calculated using data from the research team's feedback study
of 23 patients performed in 2020-21. For the primary outcome (Single Item Presence Score) at
Alpha 0.05 and power 80% a sample size of 9 per group would be required. For the secondary
outcome (Telehealth Usability Questionnaire) at Alpha 0.05 and power 80% a sample size of 40
per group would be required. The study will be powered to allow us to assess both primary and
secondary outcomes with a between subjects design. Total recruitment will be 80 patients.
Given that there is no follow up required by patients and therefore no expected loss to
recruitment during the study period, the total recruitment will be the same as the sample
size at 80 patients.
Patient Identification Patients will be recruited consecutively from the plastic surgery
clinics at the Canniesburn Plastic Surgery Unit, from the sarcoma, plastic surgery and
orthoplastic clinics under the care of the PI.
Setting The patient will attend the West Glasgow Ambulatory Care Hospital, Glasgow for the
Telemedicine clinic. The clinician will be at a remote location at the Canniesburn Plastic
Surgery Outpatient clinic, at Glasgow Royal Infirmary.
Randomisation Process Randomisation will be to 3D or 2D Telemedicine system first.
Randomisation will be blocked randomisation of unknown length, generated by computer and held
remotely by a password protected system. The research team will collect the randomisation
order when the patient attends for the study, once they have completed the consent forms for
this study.
Patient Flow in Telemedicine Clinic The patient will be reviewed by the clinician in
allocated Telemedicine system 1 for 10 minutes. They will then be reviewed on the same day by
the same clinician with Telemedicine system 2 for 10 minutes. The clinician involved will be
a Consultant, Training Grade Doctor, Physiotherapist or Nurse Specialist from the Canniesburn
Regional Plastic Surgery Unit. A number of clinicians (6 in total) will be used to reduce
potential for bias that may arise from using a single consulting clinician. They will be
fully trained in the use of the system and the research protocol. The clinical consultation
will be standardized between the two systems, to minimize bias. The questions and anatomical
areas from the first consultation will be recorded by the clinician using a study Proforma,
and used in the second consultation. The patient will subsequently fill in the study
questionnaire and complete the exit interview. The patient then requires no further
participation in the study.
Data Analysis Statistical analysis will be by independent review by the University of
Strathclyde, with results blinded for group allocation.